The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

AlterDiag will take full responsibility for the industrialization, regulatory restrictions, and commercialization of the tests.

In one, a North Carolina lab allegedly billed for unnecessary urine drug tests, and in the other a Californian women submitted fraudulent claims for respiratory pathogen testing.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

The small Baltimore-based lab is preparing for the possibility of additional appeals as years of litigation wind down.

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

NEW YORK – Roche said Wednesday that its Tina-quant Lipoprotein (a) Gen.2 Molarity assay has received 510(k) clearance from the US Food and Drug Administration. The test, which is intended for ...

Quest said that while it will continue to look at acquisition opportunities, it plans to focus on integrating and driving productivity of recently purchased assets.

NEW YORK – Danaher on Wednesday announced that the firm's Q4 2024 revenues rose 2 percent year over year as Life Sciences and Biotechnology revenues grew but Diagnostics revenues dropped. For the ...

NEW YORK – In March, a new EU-funded project will commence that aims to deliver a series of new tests and tools for diagnosing urinary tract infections in low- and medium-income countries, especially ...